Azamat Metov

We are set to become the leading vaccine facility in Russia that offers full-cycle technology. We are building the country’s first live virus manufacturing line and a range of products developed both in-house and alongside our international partners, focusing on innovative combined immunobiological drugs for the prevention and treatment of significant diseases. Within our bespoke, high-tech facility, our R&D department combines the best practices available from Russian and global companies in biotechnologies development in order to increase the accessibility of quality treatments to Russian patients. We seek to provide affordable and high-quality healthcare to all via a modern, full-cycle production facility with in-house R&D. This is created thanks to international partnership with a leading pharmaceutical company, enabling vaccine technology transfer, manufacturing, and commercialisation.